

REFERENCES

- Antignac A., Sieradzki K., and Tomasz A. (2007). Perturbation of Cell Wall Synthesis Suppresses Autolysis in *Staphylococcus aureus*: Evidence for Coregulation of Cell Wall Synthetic and Hydrolytic Enzymes. *Journal of Bacteriology*, 189, 7573-7580
- Bierbaum G., Fuchs K., Lenz W., and Szekat C. (1999). Presence of *Staphylococcus aureus* with Reduced Susceptibility to Vancomycin in Germany. *European Journal of Clinical Infectious Disease*, 18, 691-696
- Boyle-Vavra S., Challapalli M., and Daum R. S. (2003). Resistance to Autolysis in Vancomycin-Selected *Staphylococcus aureus* Isolates Precedes Vancomycin-Intermediate Resistance. *Antimicrobial Agents and Chemotherapy*, 47, 2036-2039
- Bouza E. and Burillo A. (2010). Oritavancin: a Novel Lipoglycopeptide Active Against Gram-Positive Including Multiresistant Strains. *International Journal of Antimicrobial Agents*, 36, 401-407
- Bozdogan B., Ednie L., Credito K., Kosowska K., and Appelbaum P. C. (2004). Derivatives of a Vancomycin-Resistant *Staphylococcus aureus* Strain Isolated at Hershey Medical Center. *Antimicrobial Agents and Chemotherapy*, 48, 4762-4765
- Bradford M. M. (1976). A Rapid and Sensitive Method for the Quantitation of Protein Utilizing the Principle of Protein Dye-Binding. *Annual Review of Biochemistry*, 72, 248-254
- Centers for Disease Control and Prevention (CDC). (2010). CDC Reminds Clinical Laboratories and Healthcare Infection Preventionists of their Role in the Search and Containment of Vancomycin-Resistant *Staphylococcus aureus* (VRSA). Retrieved October 5, 2010, from http://www.cdc.gov/ncidod/dhqp/ar_visavrsa_algo.html
- Chambers H. F. (2001). The Changing Epidemiology of *Staphylococcus aureus*. *Emerging Infectious Disease*, 7, 178-182
- Clauditz A., Resch A., Wieland K. P., Peschel A., and Götz F. (2006). Staphyloxanthin Plays a Role in the Fitness of *Staphylococcus aureus* and Its Ability to Cope with Oxidative Stress. *Infection and Immunity*, 74, 4950-4953
- Courvalin P. (2006). Vancomycin Resistance in Gram-Positive Cocci. *Clinical Infectious Disease*, 42, S25-S34
- Cui L., Iwamoto A., Lian J. Q., Neoh H. M., Maruyama T., Horikawa Y., and Hiramatsu K. (2006).

- Novel Mechanism of Antibiotic Resistance Originating in Vancomycin-Intermediate *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy*, 50, 428-438
- Fischetti V. A., Novick R. P., Feretti J. J., Portinoy D. A., and Rood J. I. (Eds.). (2006). Gram-Positive Pathogens (2nd ed.). Washington, DC: American Society for Microbiology Press
- Fuchs S., Pane-Farre J., Kohler C., Hecker M., and Engelmann S. (2007). Anaerobic Gene Expression in *Staphylococcus aureus*. *Journal of Bacteriology*, 189, 4275-4289
- Gross M., Cramton S. E., Götz F., and Peschel A. (2001). Key Role of Teichoic Acid Net Charge in *Staphylococcus aureus* Colonization of Artificial Surfaces. *Infection and Immunity*, 69, 3423-3426
- Hanaki H., Kuwahara-Arai K., Boyle-Vavra S., Daum R. S., and Labischinski H. (1998). Activated-Cell Wall Synthesis Is Associated with vancomycin resistance in Methicillin-Resistant *Staphylococcus aureus* Clinical Strains Mu3 and Mu50. *Journal of Antimicrobial Chemotherapy*, 42, 199-209
- Hanssen A. M., Fossum A., Mikalsen J., Halvorsen D. S., and Bukholm G. (2005). Dissemination of Community-Acquired Methicillin-Resistant *Staphylococcus aureus* Clones in Northern Norway: Sequence Types 8 and 80 Predominate. *Journal of Clinical Microbiology*, 43, 2118-2124
- Hidron A. I., Low C. E., Honig E. G., and Blumberg H. M. (2009). Emergence of Community-Acquired Methicillin-Resistant *Staphylococcus aureus* Strain USA300 as a Cause of Necrotising Community-Onset Pneumonia. *Lancet Infectious Diseases*, 9, 384-392
- Hiramatsu K. (1998). Vancomycin Resistance in Staphylococci. *Drug Resistance Updates*, 1, 135-150
- Hsu L. Y., Tristan A., Koh T. H., Bes M., Etienne j., and Kurup A. (2005). Community-Associated Methicillin-Resistant *S. aureus*, Singapore. *Emerging Infectious Disease*, 11, 341-342
- Huang H., Flynn N. M., King J. H., Monchaud C., Morita M., and Cohen S. H. (2006). Comparisons of Community-Associated Methicillin-Resistant *Staphylococcus aureus* (MRSA) and Hospital-Associated MRSA Infections in Sacramento, California. *Journal of Clinical Microbiology*, 44, 2424-2427
- Ingavale S. S., Van Wamel W., and Cheung A. L. (2003). Characterization of RAT, an Autolysis Regulator in *Staphylococcus aureus*. *Molecular Microbiology*, 48, 1451-1466
- Jariyasethpong T., Tribuddharat C., Dejsirilert S., Kerdsin A., and Tishyadhigama P. (2010).

- MRSA Carriage in a Tertiary Governmental Hospital in Thailand: Emphasis on Prevalence and Molecular Epidemiology. *European Journal of Clinical Infectious Disease*, 8, 977-985
- Jevons M. P. (1961). Celbenin-Resistant Staphylococci. *British Medical Journal*, 1, 124-125
- Koehl J. L., Muthaiyan M., Jayaswal R. K., Ehler K., Labischinski H., and Wilkinson B. J. (2004) Cell Wall Composition and Decreased Autolytic Activity and Lysostaphin Susceptibility of Glycopeptide-Intermediate *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy*, 48, 3749-3757
- Kuroda M., Kuroda H., Oshima T., Takeuchi F., Mori H., and Hiramatsu K. (2003). Two-Component System VraSR Positively Modulates the Regulation of Cell-Wall Biosynthesis Pathway in *Staphylococcus aureus*. *Molecular Microbiology*, 49, 807-821
- Ledala N., Wilkinson B. J., and Jayaswal R. K. (2006). Effect of Oxacillin and Tetracyclin on Autolysis, Autolysin Processing and *atl* Transcription in *Staphylococcus aureus*. *International Journal of Antimicrobial Agents*, 27, 518-524
- Levine D. P. (2006). Vancomycin: a History. *Clinical Infectious Disease*, 42, S5-S12
- Liu C. and Chambers H. F. (2003). *Staphylococcus aureus* with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods. *Antimicrobial Agents and Chemotherapy*, 47, 3040-3045
- Loomba P., Taneja J., and Mishra B. (2010). Methicillin and Vancomycin Resistant *S. aureus* in Hospitalized Patients. *Journal of Global Infectious Disease*, 2, 275-283
- Lulitanond A., Chanawong A., Sribenjalux P., Keawkes W., Vorachit M., and Chongtrakool P. (2006). Detection of Heterogeneous, Intermediate-Vancomycin-Resistant *Staphylococcus aureus* (hVISA) Using Low Concentration Vancomycin Disks. *Southeast Asian Journal of Tropical Medicine Public Health*, 37, 761-767
- McKay G. A., Beaulieu S., Arhin F. F., Belley A., and Sarmiento I. (2009). Time-Kill Kinetics of Oritavancin and Comparator Agents Against *Staphylococcus aureus*, *Enterococcus faecalis* and *Enterococcus faecium*, *Journal of Antimicrobial Chemotherapy*, 63, 1191-1199
- Mani N., Baddour L. M., Offutt D. Q., Vijaranakul U., Nadakavukaren M. J., and Jayaswal R. K. (1994). Autolysis-Defective Mutant of *Staphylococcus aureus*: Pathological Considerations, Genetic Mapping, and Electron Microscopic Studies. *Infection and*

Immunity, 62, 1406-1409

- Maor Y., Rahav G., Belausov N., Ben-David D., Smollan G., and Keller N. (2007). Prevalence and Characteristics of Heteroresistant Vancomycin-Intermediate *Staphylococcus aureus* Bacteremia in a Tertiary Care Center. *Journal of Clinical Microbiology*, 45, 1511-1514
- Millar B. C., Prendergast B. D., and Moore J. E. 2008. Community-Associated MRSA (CA-MRSA): an Emerging Pathogen in Infective Endocarditis. *Journal of Antimicrobial Chemotherapy*, 61, 1-7
- Mongodin E., Finan J., Climo M. W., Rosato A., Gill S., and Archer G. L. (2003). Microarray Transcription Analysis of Clinical *Staphylococcus aureus* Isolates Resistant to vancomycin. *Journal of Bacteriology*, 185, 4638–4643.
- Navarre W. W. and Schneewind O. (1999). Surface Proteins of Gram-Positive Bacteria and Mechanism of Their Targeting to the Cell Wall Envelope. *Microbiology and Molecular Biology Reviews*, 63, 174-229
- Neuhaus F. C. and Baddiley J. (2003). A Continuum of Anionic Charge: Structures and Functions of D-Alanyl-Teichoic Acids in Gram-Positive Bacteria. *Microbiology and Molecular Biology Reviews*, 67, 686-723
- Palazzo I. V. C., Araujo M. L. C. and Darini A. L. C. (2005). First Report of Vancomycin-Resistant *Staphylococci* Isolated from Healthy Carriers in Brazil. *Journal of Clinical Microbiology*, 43, 179-185
- Pfeltz R. F., Singh V. K., Schmidt J. L., Batten M. A., Baranyk C. S., Nadakavukaren M. J., Jayaswal R. K. and Wilkinson B. J. (2000). Characterization of Passage-Selected Vancomycin-Resistant *Staphylococcus aureus* Strains of Diverse Parental Backgrounds. *Antimicrobial Agents and Chemotherapy*, 44, 294-303
- Prescott L. M., Harley J. P. and Klein D. A. (Eds.). (2002). *Microbiology* (5th ed.). New York: McGraw-Hill Company
- Ramadurai L. and Jayaswal R. K. (1997). Molecular Cloning, Sequencing, and Expression of *lytM*, A Unique Autolytic Gene of *Staphylococcus aureus*. *Journal of Bacteriology*, 179, 3625-3631
- Reynolds P. E. (1989). Structure, Biochemistry and Mechanism of Action of Glycopeptide Antibiotics. *European Journal of Infectious Disease*, 8, 943-950
- Rybak M. J., Leonard S. N., Rossi K. L. and Cheung C. M. (2008). Characterization of

- Vancomycin-Heteroresistant *Staphylococcus aureus* from the Metropolitan Area of Detroit, Michigan over a 22-Year Period (1986-2007). *Journal of Clinical Microbiology*, 2950-2954
- Schafer M., Schneider T. R. and Sheldrik G. M. (1996). Crystal Structure of Vancomycin. *Journal of Structure*, 1509-1515
- Shamsudin M. N., Sekawi Z., Van Belkum A. and Neela V. (2008). First Community-Acquired Methicillin-Resistant *Staphylococcus aureus* in Malaysia. *Journal of Medical Microbiology*, 57, 1180-1181
- Sieradzki K. and Tomasz A. (1997). Inhibition of Cell Wall Turnover and Autolysis by Vancomycin in a Highly Vancomycin-Resistant Mutant of *Staphylococcus aureus*. *Journal of Bacteriology*, 179, 2557-2566
- Sieradzki K. and Tomasz A. (2006). Inhibition of Autolytic System by Vancomycin Causes Mimicry of Vancomycin-Intermediate *Staphylococcus aureus*-Type Resistance, Cell Concentration Dependence of the MIC, and Antibiotic Tolerance in Vancomycin-Susceptible *S. aureus*. *Antimicrobial Agents and Chemotherapy*, 50, 527-533
- Singh V. K., Carlos M. R., and Singh K. (2010). Physiological Significance of the Peptidoglycan Hydrolase, LytM, in *Staphylococcus aureus*. *FEMS Microbiology Letters*, 311, 167-175
- Song J. H., Hiramatsu K., Suh J. Y., Ko K. S., Ito T., Kapi M., Kiem S. and Kim Y. S. (2004). Emergence in Asian Countries of *Staphylococcus aureus* with Reduced Susceptibility to Vancomycin. *Antimicrobial Agents Chemotherapy*, 48, 4926-4928
- Srinivasan A., Dick J. D. and Perl T. M. (2002). Vancomycin Resistance in Staphylococci. *Clinical Microbiology*, 15, 430-438
- Sugai M., Yamada S., Nakashima S., Komatsuzawa H., Matsumoto A., Oshida T. and Suginaka H. (1997). Localized Perforation of the Cell Wall by a Major Autolysin: *atl* Gene Products and the Onset of Penicillin-Induced Lysis of *Staphylococcus aureus*. *Journal of Bacteriology*, 179, 2958-2962
- Trakulsomboon S., Danchaivijitr S., Rong Rungruang Y. and Dhiraputra C. (2001). First Report of Methicillin-Resistant *Staphylococcus aureus* with Reduced Susceptibility to Vancomycin in Thailand. *Journal of Clinical Microbiology*, 39, 591-596
- Utaida S., Pfeltz R. F., Jayaswal R. K. and Wilkinson B. J. (2006). Autolytic Properties of

Glycopeptide -Intermediate *Staphylococcus aureus* Mu50. *Antimicrobial Agents and Chemotherapy*, 50, 1541-1545

Wootton M., Bennett P. M., MacGowan A. P., and Walsh T.R. (2005). Reduced Expression of the *atl* Autolysin Gene and Susceptibility to Autolysis in Clinical Heterogeneous Glycopeptide-Intermediate *Staphylococcus aureus* (hGISA) and GISA Strains. *Journal of Antimicrobial and Chemotherapy*, 56, 944-947